Results 101 to 110 of about 1,066,064 (314)

Drug Logistics Service Management In Regional General Hospital Pharmacy Installations (Hospital) Undata Palu

open access: diamond, 2023
Angriani Angriani   +7 more
openalex   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Drug management of autosomal dominant polycystic kidney disease. [PDF]

open access: yesAust Prescr, 2022
Theivendran T, Ramachandran A, Rangan G.
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

open access: yesMolecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

open access: yesMolecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley   +5 more
wiley   +1 more source

Persistence with topical glaucoma therapy in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data

open access: yesBMC Ophthalmology
Background Glaucoma is the leading cause of irreversible blindness in Japan and constitutes a serious public health challenge. Due to its asymptomatic onset and slow progression, patient persistence with topical glaucoma therapies remains low ...
Kenji Kabeya   +3 more
doaj   +1 more source

The Dilemma of Treating Delirium: the Conundrum of Drug Management. [PDF]

open access: yesCurr Treat Options Oncol, 2022
Agar MR, Amgarth-Duff I.
europepmc   +1 more source

Home - About - Disclaimer - Privacy